INX-08189 + peginterferon alfa-2a + ribavirin

INX-08189 + peginterferon alfa-2a + ribavirin is a triple combination therapy developed for the treatment of **chronic hepatitis C virus (HCV) infection**.\ - **INX-08189** is an orally administered phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, acting as a potent inhibitor of HCV replication by targeting the viral RNA-dependent RNA polymerase NS5b, thereby blocking viral RNA synthesis[1][3][5].\ - **Peginterferon alfa-2a** is a pegylated recombinant interferon that induces antiviral, immunomodulatory, and antiproliferative effects through the stimulation of the host's immune response and upregulation of interferon-stimulated genes[2][4].\ - **Ribavirin** is a nucleoside analogue that interferes with viral RNA synthesis, leading to lethal mutagenesis and inhibition of viral replication[2][4].\ The combination shows synergy and increased efficacy compared to dual therapy in HCV, especially genotype 1b, with notable improvements in sustained virological response rates and a favorable safety profile[1][2][3][4][6].

Other names

6-O-methyl-2'-C-methyl guanosine phosphoramidate prodrugpegylated interferon alfa-2aribavirin